About us
Our strategy
Our strategy is to acquire promising early-stage drug candidates from academic and commercial institutions around the world, to manage the development of these drugs through preclinical testing and clinical trials, and to bring them to the market.
Development
Antisoma works with a global network of clinicians and specialist suppliers to advance its drugs through clinical trials. This website includes details of our drugs in development.
Commercialisation
Antisoma expects to take most of its drugs through development itself, and to be involved in commercialising them in at least some countries, including the United States, which is the world’s biggest market for cancer drugs. In some cases, Antisoma will form partnerships with larger pharmaceutical companies for development and/or commercialisation.
Antisoma has formed a worldwide development and marketing partnership with Novartis for ASA404, Antisoma's most advanced drug in trials. Under this partnership, Novartis is now conducting all further development and will market the drug worldwide if approved. Antisoma has an option to co-commercialise ASA404 with Novartis in the United States.
Back to top